Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · Real-Time Price · USD
2.100
-0.180 (-7.89%)
At close: Feb 20, 2026, 4:00 PM EST
2.056
-0.044 (-2.08%)
After-hours: Feb 20, 2026, 7:13 PM EST

Processa Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
5.614.785.668.764.693.26
Research & Development
7.417.275.811.496.883.17
Operating Expenses
13.0212.0511.4620.2611.576.44
Operating Income
-13.02-12.05-11.46-20.26-11.57-6.44
Interest Expense
------0.28
Interest & Investment Income
0.080.20.340.10.010
EBT Excluding Unusual Items
-12.93-11.85-11.12-20.16-11.56-6.71
Asset Writedown
----7.27--
Other Unusual Items
----0.16-
Pretax Income
-12.93-11.85-11.12-27.42-11.96-15.41
Income Tax Expense
-----0.53-1
Net Income
-12.93-11.85-11.12-27.42-11.43-14.41
Preferred Dividends & Other Adjustments
-----4.63
Net Income to Common
-12.93-11.85-11.12-27.42-11.43-19.04
Shares Outstanding (Basic)
100000
Shares Outstanding (Diluted)
100000
Shares Change (YoY)
669.62%133.30%62.83%5.16%104.27%35.71%
EPS (Basic)
-16.58-96.82-211.99-851.18-372.97-1269.40
EPS (Diluted)
-16.58-96.82-211.99-851.18-372.97-1269.40
Free Cash Flow
-10.73-11.25-8.07-9.61-8.72-3.14
Free Cash Flow Per Share
-13.76-91.90-153.75-298.12-284.52-209.56
EBITDA
-13.02-12.05-11.46-19.47-10.78-5.63
D&A For EBITDA
0000.790.790.8
EBIT
-13.02-12.05-11.46-20.26-11.57-6.44
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q